D. Friedman

发表

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.

Dereje D. Jima, Cassandra L. Jacobs, W. Choi, 2010, Blood.

Magnetic Field Exposure Assessment in a Case‐Control Study of Childhood Leukemia

S. Wacholder, J. Boice, C. Muirhead, 1997, Epidemiology.

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies

D. Brander, Joseph O. Moore, J. Gockerman, 2014, Leukemia & lymphoma.

Reflections on and future of hematologic malignancies research in the Veterans Health Administration.

K. Carson, D. Friedman, J. Weinberg, 2019, Seminars in oncology.

Childhood Exposure to Magnetic Fields: Residential Area Measurements Compared to Personal Dosimetry

S. Wacholder, J. Boice, R. Tarone, 1996, Epidemiology.

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

M. Vitek, Joseph O. Moore, J. Gockerman, 2011, Blood.

Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi‐institutional study

K. Owzar, T. Shanafelt, S. Slager, 2016, American journal of hematology.

Instructions to Authors

A. Abernethy, D. Friedman, 2002, Autonomic Neuroscience.

Partners in Oncology Care: Coordinated Follicular Lymphoma Management.

D. Friedman, W. Henderson, Mary Parker, 2019, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Statin use and need for therapy in chronic lymphocytic leukemia

D. Friedman, J. Weinberg, L. Diehl, 2010, Leukemia & lymphoma.

Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B‐cell receptor signalling

Joseph O. Moore, D. Friedman, J. Weinberg, 2018, British journal of haematology.

CD38 variation as a prognostic factor in chronic lymphocytic leukemia

R. Nipp, D. Friedman, J. Weinberg, 2014, Leukemia & lymphoma.

Perifosine as a potential novel anti-telomerase therapy

J. Shay, W. Wright, Tsung-Po Lai, 2015, Oncotarget.

Cocaine-induced pseudovasculitis.

D. Friedman, S. Wolfsthal, 2005, Mayo Clinic proceedings.

SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia

K. Owzar, L. Rassenti, T. Kipps, 2018, British journal of haematology.

A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia

Anil Potti, William T Barry, J. Nevins, 2009, Clinical Cancer Research.

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia

C. Rehder, C. Decastro, D. Rizzieri, 2007, American journal of hematology.

Patterns of microRNA expression characterize stages of human B-cell differentiation.

Dereje D. Jima, Cassandra L. Jacobs, S. Dave, 2009, Blood.

Informational needs assessment of non‐Hodgkin lymphoma survivors and their physicians

A. Abernethy, D. Friedman, A. Coan, 2010, American journal of hematology.

Utilization of the Eμ-Myc Mouse to Model Heterogeneity of Therapeutic Response

J. Nevins, T. Tan, S. Mori, 2014, Molecular Cancer Therapeutics.

Companion Diagnostics and Cancer Biomarkers Utilization of the E l-Myc Mouse to Model Heterogeneity of Therapeutic Response

J. Nevins, T. Tan, S. Mori, 2014 .

Title : Utilization of the E μ-Myc Mouse to Model Heterogeneity of Therapeutic Response Running Title : Mouse model of human lymphoma therapy heterogeneity

J. Nevins, T. Tan, S. Mori, 2014 .

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function

T. Tedder, G. Venturi, T. Matsushita, 2013, Leukemia.

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells

S. Pizzo, J. Gockerman, D. Friedman, 2010, Leukemia.

Residential exposure to magnetic fields and acute lymphoblastic leukemia in children.

W T Kaune, S Wacholder, S. Wacholder, 1997, The New England journal of medicine.

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

M. Datto, C. Rehder, C. Decastro, 2012, Leukemia & lymphoma.

Clinical and Biological Relevance of Genomic Heterogeneity in Chronic Lymphocytic Leukemia

J. Lucas, D. Friedman, J. Weinberg, 2013, PloS one.

Lipids and Their Effects in Chronic Lymphocytic Leukemia

D. Friedman, 2016, EBioMedicine.

Comparison of the PI3K-δ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro

D. Brander, D. Friedman, J. Weinberg, 2012 .

Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience

M. Kelley, D. Friedman, A. Halwani, 2022, JCO clinical cancer informatics.

Review of targeted cancer therapies for the palliative care provider PART 2: ANTIBODIES AND CONJUGATED AGENTS

A. Abernethy, D. Friedman, 2007 .

Case-control evaluation of breast cancer screening efficacy.

N. Dubin, D. Friedman, Dana R. Friedman, 1991, American journal of epidemiology.

Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system.

N. Munshi, M. Brophy, D. Friedman, 2021 .

Veterans with blood cancers: Clinical trial navigation and the challenge of rurality.

D. Friedman, S. Yellapragada, Thomas D. Rodgers, 2023, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

Review of targeted cancer therapies for the palliative care provider: Part 1: small molecules

A. Abernethy, D. Friedman, 2007 .

Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

N. Jiang, J. Gockerman, D. Friedman, 2010 .

Perifosine as a potential novel anti-telomerase therapy

J. Shay, W. Wright, Tsung-Po Lai, 2015, Oncotarget.

“Primum non nocere”: the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia

D. Friedman, 2013, Leukemia & lymphoma.